A decision-analysis tool for benefit-risk assessment of nonprescription drugs

Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2013, Pages 475-482

  Brass, Eric P ^a   Lofstedt, Ragnar ^b   Renn, Ortwin ^c  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Benefit risk; Decision analysis; Nonprescription drugs; OTC drugs

Indexed keywords

NICOTINE; NON PRESCRIPTION DRUG;

CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; CONSENSUS; DELPHI STUDY; DRUG MARKETING; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; MANAGEMENT; MEDICAL LITERATURE; NICOTINE REPLACEMENT THERAPY; PEER REVIEW; PHARMACIST; PHARMACODYNAMICS; POISON CENTER; PRESCRIPTION; PROBABILITY; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SCORING SYSTEM; SELF CONCEPT; SMOKING; SMOKING CESSATION;

DECISION SUPPORT TECHNIQUES; HUMANS; NONPRESCRIPTION DRUGS; RISK ASSESSMENT; TOBACCO USE CESSATION PRODUCTS;

EID: 84880163328     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.22     Document Type: Review

References (34)

1. Mussen F, Salek S, Walker S.Aquantitative approach to benefit-risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiol Drug Saf. 2007;16 (suppl 1):S2-S15. (Pubitemid 47180358)
2. Lynd LD, Marra CA, Najafzadeh M, Sadatsafavi M. A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework. Pharmacoepidemiol Drug Saf. 2010;19(11): 1172-1180.
3. Levitan BS, Andrews EB, Gilsenan A, et al. Application of the BRAT framework to case studies: observations and insights. Clin Pharmacol Ther. 2011;89(2):217-224.
4. Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther. 2011;89(2):312-315.
5. Brass EP. Changing the status of drugs from prescription to over-thecounter availability. N Engl J Med. 2001;345(11):810-816.
6. Francis SA, Barnett N, Denham M. Switching of prescription drugs to over-The-counter status: is it a good thing for the elderly? Drugs Aging. 2005;22(5):361-370. (Pubitemid 41003066)
7. Eickhoff C, Hammerlein A, Griese N, Schulz M. Nature and frequency of drug-related problems in self-medication (over-thecounter drugs) in daily community pharmacy practice in Germany. Pharmacoepidemiol Drug Saf. 2012;21(3):254-260.
8. Smith SC, Jr. Bridging the treatment gap. Am J Cardiol. 2000; 85(12A):3E-7E.
9. Fuster V. A new perspective on nonprescription statins: an opportunity for patient education and involvement. Am J Cardiol. 2007;100(5):907-910. (Pubitemid 47268288)
10. Gotto AM, Jr. The case for over-the-counter statins. Am J Cardiol. 2004;94(6):753-756. (Pubitemid 39221493)
11. Tinetti ME. Over-the-counter sales of statins and other drugs for asymptomatic conditions. N Engl J Med. 2008;358(25):2728-2732. (Pubitemid 351860868)
12. Barter PJ, Rye KA. Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins. Circulation. 2006;114(12):1315-1320; discussion 1320. (Pubitemid 44402058)
13. Brass EP, Lofstedt R, Renn O. Improving the decision-making process for nonprescription drugs: a framework for benefit-risk assessment. Clin Pharmacol Ther. 2011;90(6):791-803.
14. Phillips L. Decision theory its relevance to pharmaceutical medicine. In: Mann R, Rawlins M, Autry R, eds. Textbook of Pharmaceutical Medicine. Carnforth, UK: Parthenon; 1993:247-255.
15. Ferguson N. The Ascent of Money. New York: Penquin Press; 2008.
16. Brass E, Weintraub M. Label development and the label comprehesion study for over-the-counter drugs. Clin Pharmacol Ther. 2003;74:406-412. (Pubitemid 37357719)
17. Leonard-Segal A, Shay LE, Shetty D, Schiffenbauer J. Unique role of consumer studies in nonprescription drug development. J Am Pharm Assoc (2003). 2009;49(5):670-673.
18. Melin JM, Struble WE, Tipping RW, et al. A consumer use study of over-the-counter lovastatin (CUSTOM). Am J Cardiol. 2004;94(10): 1243-1248. (Pubitemid 39469941)
19. Raymond EG, Chen PL, Dalebout SM. "Actual use" study of emergency contraceptive pills provided in a simulated over-thecounter manner. Obstet Gynecol. 2003;102(1):17-23. (Pubitemid 36792116)
20. Webler T, Levine D, Rakel H, Renn O. A novel approach to reducing uncertainty: The Group Delphi. Technol Forecast Soc Change. 1991;39(3):252-263.
21. Schulz M, Renn O. Das Gruppendelphi. Konzept und Fragebogenkonstruktion. Wiesbaden Germany VS Verlag fur Sozialwissenschaften. 2009.
22. Krishnamurti T, Eggers SL, Fischhoff B. The impact of over-thecounter availability of "Plan B" on teens' contraceptive decision making. Soc Sci Med. 2008;67(4):618-627.
23. Morgan KM, DeKay ML, Fischbeck PS, Morgan MG, Fischhoff B, Florig HK.A deliberative method for ranking risks (II): evaluation of validity and agreement among risk managers. Risk Anal. 2001;21(5): 923-937. (Pubitemid 34016139)
24. Renn O, Stirling A, Muller-Herold U, et al. The application of the precautionary principle in the Eurpoean Union. Final report to the EU Commission. Univeristy of Stuttgart, Stuttgart; 2003.
25. Muller-Herold U, Morosini M, Schucht O. Choosing chemicals for precautionary regulation: a filter series approach. Environ Sci Technol. 2005;39(3):683-691. (Pubitemid 40222660)
26. Jenkins J. A United States regulator's perspective on risk-benefit considerations. Available at: http://www.fda.gov/downloads/ AboutFDA/ CentersOffices/CDER/UCM210155.pdf. Accessed April 11, 2011.
27. Fagerstrom KO, Tejding R, Westin A, Lunell E. Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tob Control. 1997;6(4):311-316. (Pubitemid 127685533)
28. Forinash AB, Pitlick JM, Clark K, Alstat V. Nicotine replacement therapy effect on pregnancy outcomes. Ann Pharmacother. 2010; 44(11):1817-1821.
29. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29(7):1422-1431. (Pubitemid 27272432)
30. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999; 13(2):238-246. (Pubitemid 29086814)
31. Shiffman S, Rolf CN, Hellebusch SJ, et al. Real-world efficacy of prescription and over-the-counter nicotine replacement therapy. Addiction. 2002;97(5):505-516. (Pubitemid 34492745)
32. Shiffman S, Hughes JR, Pillitteri JL, Burton SL. Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample. Tob Control. 2003;12(3): 310-316. (Pubitemid 39456665)
33. Hasford J, Fagerstrom KO, Haustein KO. A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur J Clin Pharmacol. 2003;59(5-6):443-447. (Pubitemid 37214952)
34. Hyland A, Bradford D, Gitchell J. Drug counselor report of adolescents abuse of nicotine replacement therapy. J Addict Dis. 2005;24(4):105-113. (Pubitemid 43334182)